EarlySight
EarlySight SA is a Swiss medtech company that develops the Cellularis retinal imaging platform, using adaptive optics transscleral flood illumination to visualize individual retinal cells (RPE, photoreceptors, RNFL) for hospital ophthalmology departments, eye clinics, pharmaceutical companies, and academic researchers seeking early detection and monitoring of retinal diseases.
- Company typePrivate
- Founded2019
- HeadquartersLausanne, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What EarlySight does
EarlySight SA is a Swiss medical device company founded in March 2019 as a spin-off from EPFL's Laboratory of Applied Photonics Devices. The company develops and commercializes the Cellularis retinal imaging platform, which combines Adaptive Optics Transscleral Flood Illumination (AO-TFI) with AI-driven image analysis to visualize individual retinal cells — retinal pigment epithelium (RPE), photoreceptors, retinal nerve fiber layer, and retinal vessels — that are invisible with standard hospital instruments. The technology is protected by U.S. Patent No. 11,179,033, exclusively licensed from EPFL, and the company holds ISO 13485:2016 certification.
The current commercial product, Cellularis Discovery, is a high-resolution ophthalmic camera sold to hospital ophthalmology departments and eye clinics for early detection and monitoring of retinal diseases such as AMD, glaucoma, and CSCR. EarlySight sells the device through a direct enterprise field-sales motion led by a Global Head of Business Development and supported by an extensive Key Opinion Leader network spanning Jules-Gonin Eye Hospital, Columbia University Medical Center, Inselspital Bern, and Hôtel-Dieu Paris. Revenue is generated primarily through hardware sales, with a planned SaaS/AI-analysis component via the December 2025 integration with RetinAI Discovery, and a developing pharma/biotech services arm providing cellular-resolution imaging endpoints for clinical trials. The company is preparing U.S. FDA submission to expand into North America and has a second-generation Cellularis platform in development.
The firm is venture-backed at seed stage with CHF 6.1 million raised across May 2021 and September 2025 rounds from Verve Ventures, Nina Capital, Zürcher Kantonalbank, NovaCapital, and CADFEM, supplemented by FIF grants. The team comprises approximately ten people including four co-founders, and the company's first production run sold out in April 2023, with clinical usage exceeding 1,000 patients and 18,000+ retinal images analyzed across multiple hospital partnerships.
EarlySight firmographics
Firmographics- Name
- EarlySight
- Legal name
- EarlySight SA
- Website
- https://earlysight.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- EarlySight SA is a Swiss medtech company that develops the Cellularis retinal imaging platform, using adaptive optics transscleral flood illumination to visualize individual retinal cells (RPE, photoreceptors, RNFL) for hospital ophthalmology departments, eye clinics, pharmaceutical companies, and academic researchers seeking early detection and monitoring of retinal diseases.
- Ownership category
- akta.pro rank
EarlySight industry classification
Industry- Product category
- Ophthalmic Diagnostic Imaging Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Measuring & Controlling Devices, Nec (3829)
- akta.pro primary industry
- Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)
- akta.pro secondary industries
- Retina & Vitreous Specialists (HLAKAKAE), Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN)
Keywords
Where EarlySight is headquartered
LocationHeadquarters
- HQ city
- Lausanne
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
EarlySight business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D
Revenue model
- Cellularis Hardware Sales: Sale of the Cellularis Discovery ophthalmic camera — a high-performance retinal imaging device sold to hospitals, eye clinics, and clinical research institutions. First production run sold out in April 2023. Revenue model is hardware-first with potential recurring software/AI analysis services.
- AI-Powered Analysis Software / SaaS: AI-driven software for image analysis and biomarker detection integrated with the hardware platform. Combined solution with RetinAI Discovery for data management, automated image interpretation, longitudinal tracking, and disease progression modeling. Potential recurring SaaS component for software analysis.
- Pharmaceutical and Clinical Research Services: Targeting pharmaceutical companies for use in drug development and clinical trials, where cellular-resolution imaging provides objective clinical endpoints for early-stage treatments. Growing collaborations with pharma companies to develop next-generation treatments.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
EarlySight product offering
Product offeringCore offering
EarlySight develops and sells the Cellularis Discovery ophthalmic camera, a high-performance retinal imaging device that uses patented Adaptive Optics Transscleral Flood Illumination (AO-TFI) to capture cellular-level images of the retina. The device enables visualization of individual retinal pigment epithelium (RPE) cells, photoreceptors, and retinal nerve fiber layer at single-cell resolution, providing approximately 10 times more detail than standard hospital imaging instruments. AI-powered software analyzes these images to detect and monitor disease biomarkers, supporting early diagnosis and treatment monitoring of retinal diseases such as AMD, glaucoma, and diabetic retinopathy.
Product overview
EarlySight offers a unified product ecosystem centered on its Cellularis® retinal imaging platform. The current commercial product, Cellularis Discovery, is an advanced ophthalmic camera that combines hardware (adaptive optics transscleral flood illumination) with AI-powered image analysis software to deliver cellular-level visualization of retinal structures. The second-generation Cellularis platform is under development for expanded global commercialization and U.S. regulatory approval. The platform is designed for ophthalmologists, researchers, and pharmaceutical companies for early disease detection, monitoring, and clinical trial endpoints.
Differentiator
Problem solved
Functional benefit
Products and services
- Cellularis Discovery Advanced ophthalmic camera delivering cellular-level images of retinal structures including retinal pigment epithelium (RPE), photoreceptors, retinal nerve fiber layer, and retinal blood vessels. Uses patented Adaptive Optics Transscleral Flood Illumination (AO-TFI) technology providing 10x more detail than standard hospital instruments. Designed for ophthalmologists, clinical researchers, and pharmaceutical companies for early disease detection, progression monitoring, and clinical trial endpoints.
Quantifiable outcome
- Over 1,000 patients scanned and 18,000+ retinal images analyzed as of September 2025, demonstrating clinical validation and technology adoption.
- +4 more outcomes
Companies that use EarlySight
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles3 records
EarlySight technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature5 records
EarlySight partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- RetinAI U.S. Inc. / Ikerian AGcoreStrategic collaboration to integrate EarlySight's Cellularis® imaging system with RetinAI's AI-driven clinical workflow and data analysis platform, RetinAI Discovery®. Combines EarlySight's breakthrough adaptive optics imaging technology with RetinAI's multimodality data management and advanced AI analytics. Enables automated image interpretation, longitudinal tracking, and disease progression modeling. Joint research and pharmaceutical collaborations planned. Both companies are Swiss innovators attending FLORetina ICOOR 2025 together.
- Jules-Gonin Eye HospitalcoreMajor Swiss ophthalmology hospital and key clinical research collaborator. Close partnership with EarlySight's founders from EPFL to obtain first clinical results on patients. Conducted clinical trial NCT04398394. Multiple joint peer-reviewed publications on RPE imaging, AMD, and CSCR.
- EPFL (Swiss Federal Institute of Technology in Lausanne)coreEarlySight was founded as a spin-off from EPFL's Laboratory of Applied Photonics Devices, led by Prof. Christophe Moser. EarlySight holds exclusive license to key patents invented by co-founders before company incorporation. Ongoing research collaboration with EPFL labs.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
EarlySight competitors and assessment
Company assessmentDirect peers
- Heidelberg Engineering: Heidelberg Engineering is a German-based leader in ophthalmic imaging, best known for the Spectralis platform combining OCT and scanning laser ophthalmoscopy. It is the most directly comparable peer to EarlySight, as both target cellular/microstructural retinal imaging for clinical and research ophthalmology, though Heidelberg focuses on multimodal OCT/SLO rather than transscleral adaptive optics.
- Optos (Nikon Healthcare): Optos, now part of Nikon, is a pioneer in ultra-widefield retinal imaging with its scanning laser ophthalmoscope technology. It directly competes in the retinal imaging device category for ophthalmology clinics, offering complementary widefield imaging compared to EarlySight's cellular-level depth.
- iCare Finland Oy: iCare Finland (which acquired Centervue) is a specialist in retinal imaging and glaucoma diagnostics, including the DRSplus fundus camera and MAIA microperimetry devices. It is a direct peer in the ophthalmic imaging device category serving eye clinics and hospitals for early disease detection.
Broad incumbents
- Carl Zeiss Meditec: Carl Zeiss Meditec is a global ophthalmic device incumbent with a broad portfolio including CIRRUS OCT, Humphrey field analyzers, and surgical microscopes. It is a broad incumbent competing in ophthalmic imaging across the same hospital and clinic customer base EarlySight targets, though its core OCT platform addresses different imaging modalities than EarlySight's cellular-level AO-TFI.
- Nidek Co., Ltd. Nidek is a Japanese manufacturer of ophthalmic equipment including fundus cameras, OCT, and laser systems. It targets the same hospital and clinic customer base as EarlySight with a broader imaging and diagnostic portfolio, making it a relevant incumbent competitor in the retinal imaging category.
- Topcon Healthcare: Topcon Healthcare is a Japanese-American provider of ophthalmic diagnostic instruments including the Triton and 3D-OCT series. It serves the same hospital and clinic ophthalmology market as EarlySight with a multi-modality imaging portfolio, making it a broad incumbent with overlapping customer relationships.
- Canon Medical Systems (Ophthalmic): Canon Medical's ophthalmic division produces the CR-2 AF and CX-1 fundus cameras used widely in retinal imaging. It is a broad incumbent in the same ophthalmic imaging device category as EarlySight, serving hospitals and clinics globally with established distribution.
Emerging players
- Phoenix Technology Group: Phoenix Technology Group specializes in retinal imaging systems including confocal and adaptive optics platforms (Micron) for research and pediatric applications. It is an emerging player in cellular-level retinal imaging with meaningful overlap to EarlySight's AO-TFI value proposition, though narrower in commercial scale.
- Eyenuk, Inc. Eyenuk is an AI-driven retinal imaging diagnostics company focused on autonomous detection of diabetic retinopathy and AMD. It is an emerging player in the AI-retinal imaging space where EarlySight also competes via its AI biomarker analysis and RetinAI partnership, though Eyenuk focuses on screening rather than cellular-level visualization.
- RetinAI Medical (Ikerian AG): RetinAI Medical / Ikerian AG is a Swiss AI healthtech company whose Discovery platform manages and analyzes ophthalmic imaging data for clinics and pharma. It is now a strategic partner of EarlySight (announced December 2025) but also a partially overlapping emerging player in AI-driven retinal image analysis with growing pharma channel access.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
EarlySight social profiles
Digital presenceEarlySight compliance and trust
Trust signalCompliance1 record
EarlySight financial estimates
Financial estimateRevenue estimate
Valuation estimate
EarlySight leadership team
Management profileNumber of profiles
Profiles19 records
EarlySight funding detail
Funding detailFunding overview
Funding rounds7 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EarlySight M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EarlySight
What does EarlySight do?
EarlySight develops and sells the Cellularis Discovery ophthalmic camera, a high-performance retinal imaging device that uses patented Adaptive Optics Transscleral Flood Illumination (AO-TFI) to capture cellular-level images of the retina. The device enables visualization of individual retinal pigment epithelium (RPE) cells, photoreceptors, and retinal nerve fiber layer at single-cell resolution, providing approximately 10 times more detail than standard hospital imaging instruments. AI-powered software analyzes these images to detect and monitor disease biomarkers, supporting early diagnosis and treatment monitoring of retinal diseases such as AMD, glaucoma, and diabetic retinopathy.
Is EarlySight a public or private company?
EarlySight is a private company. It is classified as venture growth investor backed and is currently operating.
When was EarlySight founded?
EarlySight was founded in 2019. It employs 1 to 10 people.
Where is EarlySight based?
EarlySight is headquartered in Lausanne, Switzerland, in the Europe region.
How does EarlySight make money?
Three revenue lines are on record. Cellularis Hardware Sales are the primary driver. The others are AI-Powered Analysis Software / SaaS and pharmaceutical and Clinical Research Services.
Who are EarlySight's main competitors?
Direct peers on record are Heidelberg Engineering, Optos (Nikon Healthcare) and iCare Finland Oy. Broad incumbents are Carl Zeiss Meditec, Nidek Co., Ltd., Topcon Healthcare and Canon Medical Systems (Ophthalmic). Emerging players are Phoenix Technology Group, Eyenuk, Inc. and RetinAI Medical (Ikerian AG).
Does EarlySight have an API?
No public API is recorded for EarlySight.
What industry is EarlySight in?
EarlySight's product category is Ophthalmic Diagnostic Imaging Devices. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography), with a secondary code of HLAKAKAE, Retina & Vitreous Specialists. Its NAICS code is 334510 and its SIC code is 3829.